U.S. Markets open in 3 hrs 15 mins

Arbutus Biopharma Corporation (ABUS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.7900-0.0900 (-3.13%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close2.8800
Open2.8900
Bid2.7700 x 2900
Ask0.0000 x 2200
Day's Range2.7900 - 2.9200
52 Week Range0.8400 - 9.0200
Volume1,170,597
Avg. Volume8,594,118
Market Cap225.737M
Beta (5Y Monthly)2.79
PE Ratio (TTM)N/A
EPS (TTM)-2.3190
Earnings DateAug 07, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.00
  • GlobeNewswire

    Arbutus to Participate in Virtual Fireside Chat at H.C. Wainwright Hepatitis B Virus (HBV) Mini-Conference

    WARMINSTER, Pa., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (HBV) infection as well as therapies to treat coronaviruses (including COVID-19), today announced that the Company will participate in a virtual fireside chat at the H.C. Wainwright HBV Mini-Conference on Tuesday, October 20, 2020 at 10:00 am ET.Arbutus Fireside Chat Presenters:William Collier, President and CEO; Dr. Michael Sofia, Chief Scientific Officer; Dr. Gaston Picchio, Chief Development Officer; David Hastings, Chief Financial Officer; and Michael McElhaugh, Chief Business Officer.A live webcast of the virtual fireside chat can be accessed through the Investors section of Arbutus' website at www.arbutusbio.com or directly at Live Webcast. An archived replay of the webcast will be available on the Company’s website after the conference.About ArbutusArbutus Biopharma Corporation is a publicly traded (Nasdaq: ABUS) biopharmaceutical company dedicated to discovering, developing and commercializing a cure for people with chronic hepatitis B virus (HBV) infection. The Company is advancing multiple drug product candidates that may be combined into a potentially curative regimen for chronic HBV infection. Arbutus has also initiated a drug discovery and development effort for treating coronaviruses (including COVID-19). For more information, visit www.arbutusbio.com.Contact Information Investors and MediaWilliam H. Collier President and CEO Phone: 267-469-0914 Email: ir@arbutusbio.com Pam Murphy Investor Relations Consultant Phone: 267-469-0914 Email: ir@arbutusbio.com

  • GlobeNewswire

    Arbutus to Participate in Virtual Fireside Chat at Chardan’s 4th Annual Genetic Medicines Conference

    WARMINSTER, Pa., Sept. 28, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (HBV) infection as well as therapies to treat coronaviruses (including COVID-19), today announced that the Company will participate in a virtual fireside chat at Chardan’s 4th Annual Genetic Medicines Conference on Monday, October 5, 2020 at 1:00 pm ET.Arbutus Fireside Chat Presenters:William Collier, President and CEO; Dr. Michael Sofia, Chief Scientific Officer; Dr. Gaston Picchio, Chief Development Officer; and David Hastings, Chief Financial Officer.A live webcast of the virtual fireside chat can be accessed through the Investors section of Arbutus’ website at www.arbutusbio.com or directly at Live Webcast. An archived replay of the webcast will be available on the Company’s website after the conference.About ArbutusArbutus Biopharma Corporation is a publicly traded (Nasdaq: ABUS) biopharmaceutical company dedicated to discovering, developing and commercializing a cure for people with chronic hepatitis B virus (HBV) infection. The Company is advancing multiple drug product candidates that may be combined into a potentially curative regimen for chronic HBV infection. Arbutus has also initiated a drug discovery and development effort for treating coronaviruses (including COVID-19). For more information, visit www.arbutusbio.com.Contact Information Investors and MediaWilliam H. Collier President and CEO Phone: 267-469-0914 Email: ir@arbutusbio.com Pam Murphy Investor Relations Consultant Phone: 267-469-0914 Email: ir@arbutusbio.com